You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 703 Single cell analysis of phase II study of nivolumab and relatlimab in metastatic uveal melanoma reveals tumor and immune response to dual PD-1 and LAG-3 inhibition

Citation Tools

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
703 Single cell analysis of phase II study of nivolumab and relatlimab in metastatic uveal melanoma reveals tumor and immune response to dual PD-1 and LAG-3 inhibition

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Dollar J, Decatur C, Cruz A, et al
703 Single cell analysis of phase II study of nivolumab and relatlimab in metastatic uveal melanoma reveals tumor and immune response to dual PD-1 and LAG-3 inhibition
Journal for ImmunoTherapy of Cancer 2023;11:doi: 10.1136/jitc-2023-SITC2023.0703